In major bet, Biogen pays $1.5 billion for rights to a once-failed treatment for depression
The company will retain the commercial rights to a Sage Therapeutics’ drug that disappointed in its last major clinical trial.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine
Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups
Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals
Merck to pay $425M for biotech to get Covid-19 drug, but says manufacturing will be a challenge
All Coverage
advertisement
